Recruiting
Yervoy Pregnancy Surveillance Study - CA184-487
Updated: 15 February, 2018 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Location(s)
Recruiting
Treatment Options
Inclusion Criteria: - Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment Exclusion Criteria: - Women whose ipilimumab exposure is outside the window of pregnancy exposure - Pregnancies for which there is only paternal exposure to Yervoy Other protocol defined inclusion/exclusion criteria could apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
